Pablo A. Guzman - Net Worth and Insider Trading

Pablo A. Guzman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pablo A. Guzman owns 1 companies in total, including ZyVersa Therapeutics Inc (ZVSA) .

Click here to see the complete history of Pablo A. Guzman’s form 4 insider trades.

Insider Ownership Summary of Pablo A. Guzman

Ticker Comapny Transaction Date Type of Owner
ZVSA ZyVersa Therapeutics Inc 2023-01-26 Chief Medical Officer

Pablo A. Guzman Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Pablo A. Guzman Ownership Network

Ownership Network List of Pablo A. Guzman

No Data

Ownership Network Relation of Pablo A. Guzman


Pablo A. Guzman Owned Company Details

What does ZyVersa Therapeutics Inc do?

Who are the key executives at ZyVersa Therapeutics Inc?

Pablo A. Guzman is the Chief Medical Officer of ZyVersa Therapeutics Inc. Other key executives at ZyVersa Therapeutics Inc include director & Chief Executive Officer Stephen C. Glover , Chief Scientific Officer Labella Nicholas A. Jr. , and Chief Financial Officer Peter Wolfe .

ZyVersa Therapeutics Inc (ZVSA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZyVersa Therapeutics Inc (ZVSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZyVersa Therapeutics Inc (ZVSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZyVersa Therapeutics Inc (ZVSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

ZyVersa Therapeutics Inc Insider Transactions

No Available Data

Pablo A. Guzman Mailing Address

Above is the net worth, insider trading, and ownership report for Pablo A. Guzman. You might contact Pablo A. Guzman via mailing address: C/o Zyversa Therapeutics, Inc., 2200 N. Commerce Parkway, Weston Fl 33326.

Discussions on Pablo A. Guzman

No discussions yet.